Dambkowski Carl sold $738K of APGE
Dambkowski Carl (Chief Medical Officer) sold 5,500 shares of Apogee Therapeutics, Inc. (APGE) at $134.17 ($0.74M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete datapoint on insider selling activity (shares, price, total value) but does not include any new corporate, clinical, or regulatory development.
Market read
Use as a sentiment check only; absent other catalysts, it is unlikely to drive a sustained move.
What to watch
Traders may over-weight insider sales; without accompanying company news (guidance, trial results, financing), the signal is typically weak.
Background
The article is an SEC Form 4 insider transaction for Apogee Therapeutics, Inc. (APGE).
Ticker impact
Apogee Therapeutics insider Carl Dambkowski sold 5,500 shares at $134.17 on 2026-08-05 under a 10b5-1 plan, per Form 4.
Likely limited, with any impact confined to short-term sentiment rather than a durable repricing.
The filing is a primary-source Form 4 and includes exact sale size and price, but the presence of a pre-arranged 10b5-1 plan reduces interpretive signal about near-term prospects.
Market effects
Minimal; single-company insider sale with no disclosed operational or clinical catalyst.
None.
None.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish information.
Key entities
- issuerApogee Therapeutics, Inc.
Subject of the Form 4 insider sale by its Chief Medical Officer.
- insiderCarl Dambkowski
Chief Medical Officer who sold 5,500 shares under a 10b5-1 plan.
